Nintedanib Reddy (Nintedanib)

Nintedanib is used in fibrotic lung disorders and selected oncology indications, targeting pathways that drive fibroblast activity and tumor growth.

• Idiopathic pulmonary fibrosis: slows disease progression and preserves lung function.
• Systemic sclerosis‑associated interstitial lung disease: reduces decline in forced vital capacity.
• Non‑small cell lung cancer: used in combination therapy to inhibit tumor angiogenesis and growth.

• Nintedanib blocks multiple receptor tyrosine kinases—including VEGFR 1‑3, FGFR 1‑3, and PDGFR‑α/β—by binding to their ATP‑binding sites. This inhibition curtails endothelial cell proliferation, fibroblast activation, and angiogenic signaling, thereby limiting fibrotic tissue formation and tumor vascularization.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea: feeling of sickness, may be transient.
• Vomiting: occasional episodes.
• Elevated liver enzymes: increase in ALT/AST values.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury, jaundice.
• Cardiovascular events: arterial thromboembolism or myocardial infarction.
• Severe bleeding: gastrointestinal or intracranial hemorrhage.

When prescribing Nintedanib, clinicians should consider several safety measures and monitoring requirements.

• Liver function monitoring: assess ALT, AST, bilirubin before treatment and periodically.
• Gastrointestinal management: advise patients to stay hydrated and report severe diarrhea.
• Cardiovascular risk assessment: evaluate history of arterial thrombotic events.
• Bleeding risk: avoid concomitant anticoagulants unless necessary.
• Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
• Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Nintedanib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels, risk of toxicity.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.
• P‑glycoprotein inhibitors (e.g., verapamil): may raise exposure.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampicin): may reduce effectiveness.
• Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding.
• NSAIDs: increase gastrointestinal adverse events.